Parsippany, New Jersey. Edenbridge Pharmaceuticals, LLC announces that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for Etodolac Tablets, USP, a generic version of Lodine®* tablets (Etodolac Tablets). Etodolac Tablets are indicated for acute and long-term use in the management of the signs and symptoms of Osteoarthritis and Rheumatoid Arthritis. It is also indicated for the management of acute pain. Edenbridge intends to begin shipping this newly approved product shortly and it will be available in both 400mg and 500mg strengths. For more information please contact the Company directly at info@dexcelpharmausa.com.
Etodolac Tablets, USP Approval
Specialty Products
To learn more about our specialty products, vigabatrin and Yargesa®, and how you may be able to save, please visit the Products page or navigate to a product-specific page.
Specialty Products
To learn more about our specialty products, vigabatrin and Yargesa®, and how you may be able to save, please visit the Products page or navigate to a product-specific page.